Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.

Microbiology spectrum - 26 Oct 2022

Pallenberg Sophia T, Pust Marie-Madlen, Rosenboom Ilona, Hansen Gesine, Wiehlmann Lutz, Dittrich Anna-Maria, Tümmler Burkhard

Abstract excerpt

The introduction of mutation-specific combination therapy with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has substantially improved lung function and quality of life of people with cystic fibrosis (CF). Collecting deep cough swabs and induced sputum, this postapproval study examined the effect of 14- and 50-week treatment with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chloride Channel Agonists

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Metagenome

Share to Mutation

Share to Quality of Life

Source

Open in PubMed Open full text

Identifiers

PMID: 36154176
DOI: 10.1128/spectrum.01454-22
PMCID: PMC9602284

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.PMID 36154176Read ↗

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on the oropharyngeal metagenome in adolescents with cystic fibrosisSemantic proximity Read ↗

Remodelling of cystic fibrosis respiratory microbiota in response to extended Elexacaftor–Tezacaftor–Ivacaftor therapySemantic proximity Read ↗

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.Semantic proximity Read ↗

Cystic Fibrosis Airway Microbiome: Overturning the Old, Opening the Way for the NewSemantic proximity Read ↗

Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-IvacaftorSemantic proximity Read ↗

Quantitative Analysis of the Human Airway Microbial Ecology Reveals a Pervasive Signature for Cystic FibrosisSemantic proximity Read ↗

Elexacaftor/ivacaftor/tezacaftor effect on microbial density and the microbiome composition.Semantic proximity Read ↗

Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.Semantic proximity Read ↗

Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapySemantic proximity Read ↗

Clinical Insights from Metagenomic Analysis of Sputum Samples from Patients with Cystic FibrosisSemantic proximity Read ↗

Trikafta therapy alters the CF lung mucus metabolome reshaping microbiome niche spaceSemantic proximity Read ↗

Culture-enriched metagenomic sequencing enables in-depth profiling of the cystic fibrosis lung microbiotaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.